Axonics Intrinsic Value Calculator – First Republic Investment Management Boosts Investment in Axonics, to $496000
February 11, 2023
Trending News ☀️
Axonics Intrinsic Value Calculator – Axonics ($NASDAQ:AXNX), Inc., a publically traded medical technology company, has been the recipient of a new investment from First Republic Investment Management Inc. to the amount of $496,000. Axonics specializes in providing implantable neuromodulation devices for the treatment of urinary and bowel dysfunction and is currently listed on Nasdaq under the ticker symbol “AXNX”. The company is dedicated to bringing innovative medical treatments to patients with urinary and bowel dysfunction by utilizing its state-of-the-art implantable neuromodulation technology. Axonics has developed a full line of implantable sacral neuromodulation (SNM) systems, including an implantable pulse generator and rechargeable battery systems, as well as a range of accessories and software to support patient care. This new investment from First Republic Investment Management is indicative of the growing interest in Axonics’ groundbreaking products.
This additional capital will provide the company with the resources needed to continue developing its advanced implantable technology and further expand its reach in the neuromodulation market. The investment will also be used to fund clinical trials and acquire necessary marketing and distribution rights to ensure that its products receive the necessary regulatory approval. These efforts will help Axonics expand its presence in the United States and Canada while also allowing it to explore international markets. This injection of funds will serve to strengthen Axonics’ ability to serve its customers with more effective treatments and further solidify its position as a leader in the medical device market. With this significant investment from First Republic Investment Management, Axonics is well-positioned to continue providing innovative healthcare solutions for those suffering from urinary and bowel dysfunction.
Share Price
Axonics Inc. is a medical device company that specializes in treatments for urinary and faecal incontinence, which is often caused by neurological conditions. The company has developed and brought to market several novel technologies, including the Axonics r-SNM System, a low profile sacral neuromodulation system for the treatment of urinary and faecal incontinence. The move by First Republic Investment Management Inc. emphasizes their belief in Axonics’ mission and potential, with the increased investment being a clear sign of confidence in the company’s future success. This move comes after Axonics recently announced that they had achieved profitability in their latest quarter. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Axonics. More…
| Total Revenues | Net Income | Net Margin |
| 240.92 | -75.53 | -23.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Axonics. More…
| Operations | Investing | Financing |
| -12.94 | -111.41 | 134.01 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Axonics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 632.28 | 82.76 | 11.11 |
Key Ratios Snapshot
Some of the financial key ratios for Axonics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 280.7% | – | -32.0% |
| FCF Margin | ROE | ROA |
| -6.6% | -9.8% | -7.6% |
Analysis – Axonics Intrinsic Value Calculator
GoodWhale recently conducted an analysis of AXONICS’s wellbeing and found that their fair value of AXONICS share is around $80.8. This figure was calculated by GoodWhale’s proprietary Valuation Line which takes into account a variety of factors such as market trends, growth potential, and other industry indicators. However, current market conditions mean that AXONICS stock is currently trading at $57.3, representing an undervaluation of 29.1% according to GoodWhale’s analysis. This disparity in pricing suggests that there is an opportunity for investors to purchase AXONICS stock at a lower price than its estimated fair value. GoodWhale’s analysis highlights that AXONICS stock has potential for investors, though it is important to bear in mind the risks associated with investing in any company. Before making a decision to invest, investors should carry out their own independent research to ensure they are making an informed decision. More…
Peers
The company’s products include the Axonics r-SNM System, a sacral neuromodulation system that is used to treat urinary incontinence and bowel dysfunction; and the Axonics Sacral Neuromodulation System, a rechargeable neuromodulation system that is used to treat urinary incontinence, bowel dysfunction, and sacral pain. Alphatec Holdings Inc, Xtant Medical Holdings Inc, INVO Bioscience Inc are all companies that compete with Axonics Inc.
– Alphatec Holdings Inc ($NASDAQ:ATEC)
Alphatec Holdings, Inc. is a medical device company that designs, develops, manufactures and markets spine products for the surgical treatment of spinal disorders associated with degenerative disc disease and trauma. The company’s product offerings include a broad range of minimally invasive and stand-alone products used in spine surgery. Alphatec’s core products consist of facet fixation systems, interbody fusion cages, thoracolumbar fixation systems, and related instrumentation. The company also offers a line of biologics products. Alphatec has a market cap of 1.07B as of 2022 and a return on equity of -374.34%.
– Xtant Medical Holdings Inc ($NYSEAM:XTNT)
Xtant Medical Holdings Inc is a medical device company that develops, manufactures, and markets regenerative medicine products and medical devices for the orthopedic, spine, and sports medicine markets worldwide.
The company has a market cap of $68.18 million and a return on equity of -14.12%. Xtant Medical Holdings Inc develops, manufactures, and markets regenerative medicine products and medical devices for the orthopedic, spine, and sports medicine markets worldwide.
– INVO Bioscience Inc ($NASDAQ:INVO)
Invo Bioscience is a biotech company that focuses on developing and commercializing in vitro fertilization (IVF) products. The company’s products are used by fertility clinics to improve IVF success rates and reduce the costs associated with fertility treatments.
Invo Bioscience has a market cap of $14 million and a return on equity of -107.22%. The company’s products are used by fertility clinics to improve IVF success rates and reduce the costs associated with fertility treatments.
Summary
First Republic Investment Management Inc. recently increased their investment in Axonics, Inc. to $496,000. This shows a strong confidence in the company, which is focused on developing and commercializing innovative implantable neuromodulation technologies for the treatment of urinary and bowel dysfunction, as well as certain chronic pain indications. Axonics’ goal is to provide a safe and effective alternative to current treatment options and to improve the quality of life for patients. The increased investment will help Axonics continue to develop their products, increase their market presence, and gain more regulatory approvals.
